Literature DB >> 26666880

Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil to lymphocyte ratio.

Wei Wang1,2, Yufu Ye1,2, Ting Wang2, Feng Zhang2, Lei Geng1,2, Jun Yu1,2, Lin Zhou1,2, Sheng Yan1,2, Shusen Zheng1,2,3.   

Abstract

AIM: Neutrophil to lymphocyte ratio (NLR) is an inflammatory biomarker that has a close relationship with tumor progression and metastasis. In this study, we aimed to investigate the role of NLR in the prognosis of male candidates with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT).
METHODS: We analyzed the clinical data of 248 male HCC candidates who underwent LT in our Liver Transplantation Center between 2002 and 2012. All risk factors were analyzed by univariate and multivariate Cox analysis and survival rates were calculated by Kaplan-Meier log-rank test.
RESULTS: NLR was proved to be an independent risk factor affecting overall survival (OS) (P < 0.001) and tumor-free survival (TFS) (P = 0.003) of male candidates with HCC following LT. Additionally, our study showed that elevated NLR (>4) was associated with early tumor recurrence by Kaplan-Meier analysis. Furthermore, we established Model_OS and Model_TFS to predict prognosis based on multivariate Cox analysis. Our study showed that male candidates with HCC who exceeded the Milan criteria but within Model_OS could achieve similar OS as those within the Milan criteria (P = 0.220). Similarly, male patients who exceeded the Milan criteria but within Model_TFS could achieve similar TFS as those within the Milan criteria (P = 0.197).
CONCLUSION: Proper inflammatory response may effectively reduce tumor recurrence after LT. Elevated NLR (>4) within a certain range is associated with early tumor recurrence. NLR-based models are efficient and safe for prognostic prediction among male candidates with HCC for LT.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  inflammation; overall survival; recurrence; risk factor; tumor-free survival

Year:  2016        PMID: 26666880     DOI: 10.1111/hepr.12633

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

Review 1.  Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.

Authors:  Xingshun Qi; Jianjun Li; Han Deng; Hongyu Li; Chunping Su; Xiaozhong Guo
Journal:  Oncotarget       Date:  2016-07-19

Review 2.  Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma.

Authors:  Marc Najjar; Surbhi Agrawal; Jean C Emond; Karim J Halazun
Journal:  J Hepatocell Carcinoma       Date:  2018-01-18

Review 3.  Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.

Authors:  Randy C Bowen; Nancy Ann B Little; Joshua R Harmer; Junjie Ma; Luke G Mirabelli; Kyle D Roller; Andrew Mackay Breivik; Emily Signor; Alec B Miller; Hung T Khong
Journal:  Oncotarget       Date:  2017-05-09

Review 4.  Compliance with ethical standards in the reporting of donor sources and ethics review in peer-reviewed publications involving organ transplantation in China: a scoping review.

Authors:  Wendy Rogers; Matthew P Robertson; Angela Ballantyne; Brette Blakely; Ruby Catsanos; Robyn Clay-Williams; Maria Fiatarone Singh
Journal:  BMJ Open       Date:  2019-02-05       Impact factor: 2.692

Review 5.  Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Maria J Citores; Jose L Lucena; Sara de la Fuente; Valentin Cuervas-Mons
Journal:  World J Hepatol       Date:  2019-01-27

6.  Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.

Authors:  Ayman Bannaga; Ramesh P Arasaradnam
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

Review 7.  Liver Transplantation for Hepatocellular Carcinoma: How Should We Improve the Thresholds?

Authors:  Tsuyoshi Shimamura; Ryoichi Goto; Masaaki Watanabe; Norio Kawamura; Yasutsugu Takada
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

8.  The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Authors:  Jing-Houng Wang; Yen-Yang Chen; Kwong-Ming Kee; Chih-Chi Wang; Ming-Chao Tsai; Yuan-Hung Kuo; Chao-Hung Hung; Wei-Feng Li; Hsiang-Lan Lai; Yen-Hao Chen
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.